June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Molecular properties from Siempreviva plant extracts against pterygium pathogenesis
Author Affiliations & Notes
  • Judith Zavala
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Jezreel Pantaleon-Garcia
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Eduardo Camacho-Martinez
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Clarisa Michelle Arellano-Gurrola
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Daniela Enriquez-Ochoa
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Arely Anakaren Reyna-Fuentes
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Ana Karen Tello-Gomez
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Bernardo Martinez-Garcia
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Jorge E. Valdez-Garcia
    Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
    Ophthalmology Research Chair, Tec Salud, Monterrey, Mexico
  • Footnotes
    Commercial Relationships   Judith Zavala, None; Jezreel Pantaleon-Garcia, None; Eduardo Camacho-Martinez, None; Clarisa Michelle Arellano-Gurrola, None; Daniela Enriquez-Ochoa, None; Arely Anakaren Reyna-Fuentes, None; Ana Karen Tello-Gomez, None; Bernardo Martinez-Garcia, None; Jorge E. Valdez-Garcia, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4367. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Judith Zavala, Jezreel Pantaleon-Garcia, Eduardo Camacho-Martinez, Clarisa Michelle Arellano-Gurrola, Daniela Enriquez-Ochoa, Arely Anakaren Reyna-Fuentes, Ana Karen Tello-Gomez, Bernardo Martinez-Garcia, Jorge E. Valdez-Garcia; Molecular properties from Siempreviva plant extracts against pterygium pathogenesis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4367.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Non-surgical approaches to pterygium are limited to descriptive evidence, and fail to associate molecular mechanisms beyond clinical improvements. We demonstrated inhibition of pterygium fibroblast viability with extracts of Sedum spp plant and now explore the extracts modulation of pterygium pathogenesis.

Methods : Human pterygium fibroblasts (HPFs), or NIH3T3 fibroblasts (3T3) were treated with media-only (sham) or Sedum spp extracts: sap, hexane (Hex) or hexane/acetone (Hex/Ac). Cell viability, and LD50, were determined using increasing concentrations (0-2,000 mcg/mL) at 24h post-treatment by cell tittering and Probit analysis or Log regression. ECM remodeling at 2, 6 and 72h post-treatment was assessed in HPFs with release of matrix metalloproteinase 3 (MMP-3), and proliferation signaling was assessed at 6h with VEGF and CTGF by ELISA. Oxidative stress was judged by NO production with Greiss assay in RAW 264.7 cells (RAW) challenged (or not) with LPS (10 mcg/mL).

Results : Reduction in cell viability were found in sap-treated cells in HPFs and 3T3 (LD50=269 and 217mcg/mL), and with Hex/Ac treatment (847mcg/mL and 647mcg/mL respectively). MMP-3 was stable between 2 and 72h with sham, at 6h had a 3-fold increase with sap (p<0.05) against sham, no difference showed for Hex/Ac-treated HPFs. VEGF release increased (3.6-fold, p<0.05) only with sap. CTGF increased (2.3-fold, p<0.05) only with Hex/Ac vs sham. Sap extract promoted significant NO production with (p<0.05) or without (p<0.005) LPS stimulation. No difference was seen between sham- and Hex-treated RAW.

Conclusions : Sap extract is the most anti-proliferative for HPFs and 3T3, but it's associated with increased ECM remodeling, proliferation and oxidation. In addition to mild anti-proliferative effect of Hex/Ac, lack of association with pathogenic events embraces this extract for future therapeutic development.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

(A) LD50 of S. spp. extracts. (B) MMP-3 release. Left: Total protein concentration 2 and 72 h post primary culture. Right: Total protein release fold-change compared to ctl group at 24h post-treatment. (C) VEFG and CTGF in supernatants. Fold-change of total protein release compared to cctl group at 24h post-treatment. (D) Detection of NO- derivates after treatment and challenge (or not) with 10mcg/mL of LPS. (B) and (C) were analyzed with multiple paired T-test. (D) Was analyzed with 2way ANOVA using Tukey's multiple comparison test.

(A) LD50 of S. spp. extracts. (B) MMP-3 release. Left: Total protein concentration 2 and 72 h post primary culture. Right: Total protein release fold-change compared to ctl group at 24h post-treatment. (C) VEFG and CTGF in supernatants. Fold-change of total protein release compared to cctl group at 24h post-treatment. (D) Detection of NO- derivates after treatment and challenge (or not) with 10mcg/mL of LPS. (B) and (C) were analyzed with multiple paired T-test. (D) Was analyzed with 2way ANOVA using Tukey's multiple comparison test.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×